Q1 Therapeutics Earnings: AbbVie Revenue Tops Estimates, Moderna Leads Growth

Earnings
โดย Yahoo Finance·Read original
Summary · why it matters

AbbVie reported first-quarter revenues of $15 billion, up 12.4% year on year and exceeding analysts' expectations by 1.7%. Among the 11 therapeutics stocks tracked, Moderna delivered the fastest revenue growth with $389 million, a 260% increase that beat estimates by 55.8%. United Therapeutics posted the weakest performance, with revenues of $781.5 million, down 1.6% and missing expectations by 1.9%. Vertex Pharmaceuticals reported $2.99 billion in revenue, up 8.2% and beating estimates by 1.2%, while Halozyme Therapeutics recorded $376.7 million, up 42.2% and exceeding expectations by 6.1%. Overall, the group's revenues surpassed consensus estimates by 14.5%, and share prices have risen an average of 18.9% since the latest earnings results.

Impact on stocks 5

Biotech & Genomic Medicine± Mixed · 5 stocks
AbbVie Inc
ABBV
▲ PositiveCapitalrelevance

AbbVie reported Q1 revenues of $15B, up 12.4% YoY and beating estimates by 1.7%.

Halozyme Therapeutics Inc
HALO
▲ PositiveCapitalrelevance

Halozyme Therapeutics recorded $376.7M revenue, up 42.2% and exceeding expectations by 6.1%.

Moderna Inc
MRNA
▲ PositiveCapitalrelevance

Moderna delivered fastest revenue growth with $389M, a 260% increase beating estimates by 55.8%.

© 2026 MarketDXNews